PriMera Scientific Surgical
Research and Practice
Volume 8 Issue 3 September 2026
DOI: 10.56831/PSSRP-08-326
ISSN: 2836-0028

Novel Nutritional Formulations for Post-Stroke Rehabilitation: Scientific Potential and Clinical Applications

Type: Review Article
Received: June 22, 2026
Published: September 02, 2026

Citation:
Christina Rahm. "Novel Nutritional Formulations for Post-Stroke Rehabilitation: Scientific Potential and Clinical Applications". PriMera Scientific Surgical Research and Practice 8.3 (2026): 21-28.

Christina Rahm*

DRC VENTURES LLC, USA

***Corresponding Author:** Christina Rahm, DRC VENTURES LLC, USA.

Abstract

Stroke is a major cause of mortality and long-term disability in most countries of the world, with about 795,000 Americans developing stroke every year. The conventional post-stroke rehabilitation has been based on the use of pharmaceuticals and physical therapy. However, major gaps still exist to maximize the outcomes of neurological recovery and functional outcomes. This white paper will discuss a new patent-pending treatment protocol that utilizes three proprietary nutritional formulations that are being used under a structured dosing schedule to treat post-stroke rehabilitation. The strategy combines zeolite extracts, amino acids, polyphenolic compounds, and the use of different bioactive components, which may stimulate neural repair, lower inflammation, and functional restoration. This paper assesses the scientific rationale of every element of the formulation, the possible action mechanisms, and the prospects of making contributions to the development of stroke rehabilitation research and clinical practice.

Introduction

The Burden of Stroke

Strokes or cerebrovascular accidents are one of the most serious health problems in the world that impact millions of people every year and cause significant financial losses to healthcare systems. Stroke pathophysiology may be either ischemia, which is the blockage of arteries in the brain and hinders blood flow to the brain, or hemorrhage, which is the bursting of a vessel in the head (Donnan et al., 2008). Both types of stroke cause acute oxygen and nutrient deficits to the neural tissue, triggering cascades of cell death, inflammation, and oxidative stress, which lead to neurological impairments (Dirnagl et al., 1999).

The therapeutic paradigms that are currently applied to post-stroke rehabilitation are largely focused on pharmacological management and physical, occupational, and speech therapy (Winstein et al., 2016). Even with such multimodal strategies, large numbers of stroke survivors have been burdened with residual functional deficits, cognitive deterioration, and poor quality of life. Complementary and integrative interventions, such as nutritional supplementation, have been considered as a remedy to the extensive gaps in the current knowledge of innovative interventions to improve neuroplasticity, tissue repair, and functional recovery.

Rationale for Nutritional Intervention

There is developing evidence to indicate that certain components of dietary intake and bioactive compounds can mediate stroke recovery in a variety of mechanisms, such as neuroprotection, anti-inflammatory actions, improvement of cerebral blood flow, and neuroplasticity maintenance. The patent-pending formulations discussed in this paper are a systematic effort to combine varying bioactive compounds with synergistic mechanisms into a structured treatment regimen with the special objective of post-stroke rehabilitation.

Formulation Components and Scientific Rationale

First Formulation: Zeolite-Based Complex

The first proprietary formulation comprises zeolite extract, ascorbic acid, sea mineral concentrate, and potassium sorbate in an aqueous base. Each component contributes distinct potential benefits:

Zeolite Extract: Zeolites are aluminosilicate microporous minerals that have drawn scientists' attention due to their probable detoxification ability and capacity to regulate oxidative stress. Studies indicate that the zeolites can adsorb reactive oxygen species and heavy metals, which could mitigate oxidative neural tissue damage during the stroke (Lamprecht et al., 2015; Mastinu et al., 2019). Zeolite supplementation showed intestinal barrier integrity and redox biology parameter effects in aerobically trained subjects and may have systemic antioxidant effects.

Ascorbic Acid (Vitamin C): This is an important water-soluble antioxidant that has a vital role in neuroprotection, which involves free radical scavenging, other antioxidant regeneration, and collagen production (Vital to vascular integrity), all necessitating water solubility (May, 2012). The epidemiological literature has implicated the elevated levels of vitamin C with a lower risk of stroke, and experimental data indicate the possibility of benefit in the treatment of acute stroke by lowering the levels of oxidative stress and improving the barrier of the blood-brain barrier in protection.

Sea Mineral Concentrate: Marine-based mineral complexes contain trace elements such as magnesium that have been shown to have neuroprotective effects in models of stroke by antagonizing calcium channels and reducing excitotoxicity. Magnesium in vascular activity and blood pressure could be beneficial to cerebrovascular health in the recovery period.

Second Formulation: Amino Acid and Phytochemical Complex

The second formulation integrates L-tyrosine, caffeine anhydrous, L-theanine, Mucuna pruriens, pine bark extract, turmeric root extract, and vitamin D3.

L-Tyrosine: L-Tyrosine can be used as a precursor of catecholamine neurotransmitters such as dopamine, norepinephrine, and epinephrine, which are essential in motor performance, thinking, and mood regulation; areas that are often impaired after stroke (Fernstrom & Fernstrom, 2007). Theoretically, the synthesis of neurotransmitters under increased metabolic needs of neural repair during supplementation could be facilitated.

L-Theanine: L-theanine is an amino acid that is commonly found in tea leaves and exhibits anxiogenic effects and is said to improve cognitive performance and induce alpha-wave brain activity that correlates with relaxed alertness (Nobre et al., 2008). Its possible neuroprotective effects should be examined in stroke conditions, especially considering that it can regulate mental state without sedation.

Mucuna pruriens: This is a legume that naturally has L-DOPA, the direct precursor of dopamine, and has been tested in Parkinson's disease as a dopaminergic compound (Katzenschlager et al., 2004). Since dopaminergic signaling is involved in motor recovery and neuroplasticity after stroke, this botanical compound has theoretical advantages that should be evaluated in detail.

Pine Bark Extract: Pine bark extract is a potent antioxidant and anti-inflammatory extract rich in proanthocyanidins and other phenolic compounds (Rohdewald, 2002). It has been shown that there are possible origins of improvement in vascular functions by improving the production of nitric oxide and endothelial functions, which would theoretically benefit cerebral perfusion in the case of stroke recovery.

Turmeric Root Extract (Curcuminoids): The main bioactive ingredient of turmeric is curcumin, which has undergone extensive research on its neuroprotective effect through the antioxidant, anti-inflammatory, and anti-apoptotic pathways. The preclinical models of stroke have shown that administration of curcumin has the potential to reduce the volume of the infarct and enhance neurological outcomes by a variety of mechanisms (Zhao et al., 2010). Other research has also depicted the action of curcumin in inhibiting ischemic brain injury via the Akt/Nrf2 pathway (Wu et al., 2013) and in curcumin regulating microglia/macrophage polarization (Liu et al., 2017), but bioavailability limitations have hampered clinical implementation.

Vitamin D3: In addition to its classical action in calcium homeostasis, vitamin D acts as a neurosteroid having various effects on the health of the brain, such as the regulation of neuroplasticity, neuroprotection, and inflammatory mechanisms (Garcino et al., 2002). Poorer outcomes and a higher risk of stroke have been linked to vitamin D deficiency, which indicates the possible positive effects of repletion or supplementation.

Third Formulation: Polyphenol and Metabolic Support Complex

The third formulation contains raspberry ketones, turmeric curcuminoids, resveratrol, D-ribose, apple cider vinegar, pine bark extract, black cumin oil, with substantial proportions of flavoring agents and purified water.

Resveratrol: This is a polyphenolic compound that has attracted a lot of research attention in the areas of cardiovascular and neuroprotective properties that can be found in grapes and berries. Resveratrol is a sirtuin and other longevity-related agonist, anti-inflammatory, and has the potential to improve blood flow through the brain (Tellone et al., 2015). Preclinical stroke studies show that resveratrol leads to reduced infarct volumes and positive functional outcomes, and has protective effects on oxidative stress in a middle cerebral artery occlusion model (Sinha et al., 2002).

D-Ribose: This five-carbon sugar is used in the structure of ATP and can hypothetically be used to energize metabolism in cells in the process of high-energy-demand neural repair and recovery.

Black Cumin Oil (Nigella sativa) is a botanical oil that has been shown to contain thymoquinone and other bioactive constituents and has been shown to have antioxidant, anti-inflammatory, and neuroprotective properties in test animals.

Proposed Mechanisms of Action

Oxidative Stress Mitigation

The pathophysiology of stroke includes a considerable production of reactive oxygen species by several mechanisms, such as mitochondrial dysfunction, inflammatory cell infiltration, and reperfusion injury (Allen & Bayraktutan, 2009). The formulas have various antioxidant substances in them, such as ascorbic acid, curcuminoids, resveratrol, and pine bark extract, which theoretically are capable of working together to neutralize free radicals, curb lipid peroxidation, and prevent oxidation of cellular membranes and proteins.

Neuroinflammation Modulation

Inflammatory mechanisms in the post-stroke encompass microglia activation, peripheral immune cell infiltration, and pro-inflammatory cytokine release that cause secondary damage and impair recovery (Iadecola & Anrather, 2011). Some of the components of the formulations, especially curcuminoids, resveratrol, and black cumin oil, have anti-inflammatory effects by inhibiting the inflammatory signaling pathways. It has been specifically shown that curcumin is capable of regulating the polarization of microglia, changing it from pro-inflammatory to anti-inflammatory (Liu et al., 2017).

Neurotransmitter Support and Neuroplasticity Enhancement

Neuroplastic reorganization, i.e., development of new synaptic connections and recruitment of perilesional and contralesional brain areas, is essential to the recovery of function following stroke (Murphy & Corbett, 2009). The amino acids L-tyrosine and L-DOPA are amino acid precursors that may be involved in catecholaminergic neurotransmission, which is essential in motor learning and cognitive recovery (Fernstrom & Fernstrom, 2007).

Vascular Function and Cerebral Perfusion

Cerebral blood flow optimization is important during stroke recovery to provide oxygen and nutrients to viable tissue that is still compromised. Pine bark extract, resveratrol, has the potential to improve the endothelial functioning and bioavailability of nitric oxide, which could improve the microvascular perfusion (Rohdewald, 2002).

Structured Dosing Protocol: Scientific Considerations

The patent gives an account of a progressive dosing pattern in which administration of the formulations is increased with time. The strategy should be considered in several ways:

Dose Escalation Rationale: The gradual addition of bioactive compounds can lead to tolerance testing, reduction of possible adverse effects, and optimization of the response of each patient. This is similar to the pharmacological principles used in the titration of medications.

Timing Considerations: The dosing schedules and timelines mentioned may be based on speculations about the best time frames of intervention during diverse stages of stroke recovery- the acute, subacute, and chronic stages entail different pathophysiological events that might possibly be benefited by custom-made nutritional support (Dirnagl et al., 1999).

Combination Strategy: Co-administration of three formulations with complementary effects is a multi-targeted treatment of the pathology of stroke, taking into account several factors.

Potential Contributions to Scientific Advancement

Novel Research Directions

The following are just some of the avenues that this patent-pending method opens to scientific research:

Mechanistic Studies: The precise mechanisms by which individual components and combinations thereof can affect the stroke recovery processes, incorporating neuroprotection, neuroplasticity, and functional restoration, can be clarified with appropriate rigorous preclinical research. Since the individual effects of such components as curcumin have been shown to have an impact on various pathways (Wu et al., 2013; Zhao et al., 2010), systematic exploration of synergistic actions would further develop the understanding of multi-targeted therapies.

Biomarker Development: Clinical trials that use these formulations may include the evaluation of biomarkers of oxidative stress and inflammation, neurotrophic factors, and metabolic parameters that identify responders and optimize treatment regimens.

Comparative Effectiveness Research: A comparison with regular rehabilitation interventions would determine the incremental benefits or lack thereof of nutritional supplementation in stroke recovery (Winstein et al., 2016).

Translational Opportunities

Translational research is made more efficient and is achieved through the integration of various evidence-based nutritional elements into standardized formulations, which would offer reproducible interventions to be used in clinical trials. The main research questions are the following:

- Which is the best time, and how long should the nutritional intervention last in comparison to the occurrence of the stroke?
- What subtypes of strokes and patient populations can benefit most with the help of particular components of the formulation?
- What is the interaction between these nutritional methods and traditional pharmacological and rehabilitation treatment methods?
- How safe and effective is it in the long run in various groups of patients?

Personalized Medicine Applications

The personal differences in nutritional health, the genetic polymorphism of nutritional metabolism, and the heterogeneity of stroke etiology and severity have implied the possibility of a personal approach. Subsequent studies may be able to determine biomarkers or genetic variations related to response to individual formulation ingredients, allowing a range of nutritional interventions to be customized to respond in relation to the specific patient characteristics.

Clinical and Regulatory Considerations

Evidence Requirements

This patent-pending approach requires a strict assessment of clinical practice by conducting properly designed clinical trials. Phase I research ought to determine the safety and tolerability in a wide range of patients. Phase II trials would then offer early efficacy signals and dose optimization information, and then be followed by sufficiently powered Phase III randomized controlled trials of the formulations versus placebo or standard care (Winstein et al., 2016).

Quality Control and Standardization

Nutritional supplements have issues associated with inconsistency in bioactive components levels, stability, and bioavailability. The quality control, standardization of extract compositions, and validation of methods of analysis are essential requirements of scientific development in order to support reproducibility of research studies, as well as clinical use (Rohdewald, 2002).

Safety Monitoring

Most of the formulation components have a proven safety profile when taken alone, but when they are combined, they must undergo a thorough safety assessment. The possibility of interaction with the drugs that are regularly prescribed to stroke victims should be investigated thoroughly. As an illustration, dopaminergic activity of Mucuna pruriens is established in Parkinson's disease (Katzenschlager et al., 2004), although the interactions with stroke drugs need to be studied specifically.

Limitations and Critical Appraisal

Evidence Gaps

The case studies contained in the patent application are limited and cannot replace proper clinical trials with proper set controls, sufficient sample sizes, and valid outcome measures. The mechanisms postulated are mostly theoretical until they are proven by experimental means. Existing data on single constituents is mostly based on preclinical models (Sinha et al., 2002; Zhao et al., 2010) and not clinical trials on stroke in humans.

Bioavailability Challenges

A large proportion of these bioactive compounds, including curcuminoids and resveratrol, have been well-documented to have bioavailability constraints, which can significantly lower their systemic and central nervous system exposure. Higher dosing schedules or methods of finding the best dosing regimen could be required in order to get therapeutically relevant tissue concentrations. These neuroprotective effects have only been shown in animal models, and unless these pharmacokinetic issues are addressed, there may not be a direct correlation with human applications.

Complexity of Multi-Component Formulations

Although combination approaches have a theoretical benefit, this makes them more difficult to understand mechanistically and identify active components. Future studies ought to incorporate studies examining the various components and combinations of the components to determine the components that add value to the overall effects observed and whether more simplified formulations can offer similar gains. It is complicated by the fact that the effects of particular compounds cannot be ascribed to particular compounds due to the complexity of three distinct formulations containing multiple ingredients each.

Future Research Agenda

In order to promote the scientific knowledge and clinical practice of these formulations, a wide-ranging research program must cover:

Preclinical Investigations

- Experimental models of animal stroke, which test individual parts and combinations.
- Mechanistic analyses of effects on oxidative stress (Allen & Bayraktutan, 2009), inflammation (Iadecola & Anrather, 2011), and neuroplasticity (Murphy & Corbett, 2009).
- Drug kinetics and dynamics description.
- Dose-Response and Ideal time of intervention.

Clinical Research

- Phase I safety and tolerability studies in stroke survivors
- Phase II proof-of-concept trials with biomarker assessments
- Phase III randomized controlled trials with functional outcome measures following established stroke rehabilitation guidelines (Winstein et al., 2016)
- Long-term observational studies assessing sustained benefits and safety

Translational Studies

- Patient selection and response prediction biomarker identification.
- Research on formulation-drug interactions.
- Design of optimal delivery systems containing bioavailability issues.
- Cost-effectiveness analysis of economics.

Conclusion

The patent-pending formulations and treatment regimen are a novel method of post-stroke rehabilitation incorporating various bioactive nutritional factors and other complementary mechanisms of oxidative stress, inflammation, neurotransmitter activity, and vascular wellbeing. The scientific basis of specific formulation constituents is based on considerable amounts of preclinical and clinical data of proven neuroprotective activity of curcumin, resveratrol, and other bioactive substances.

The strategy has served to promote the further development of science, through the suggestion of a multi-targeted nutritional intervention that tackles different facets of stroke pathophysiology and offers a systematic and reproducible protocol to be used in systematic clinical studies, the identification of individual bioactive compounds and combinations to be the focus of mechanistic research, and the creation of alternatives in nutritional approaches based on personal patient characteristics.

Nevertheless, to achieve this potential, it is necessary to dedicate itself to intensive scientific testing, such as a duly designed clinical test, mechanistic research to explain the biological effects, and proper consideration of safety, quality control, and standardization. The preliminary case study data, although promising, are only a pilot view and need to be validated with the use of controlled research in

order to be responsibly recommended for use in clinical practice.

With the current development of the science of nutritional neuroscience, the pursuit of integrative strategies that might incorporate evidence-based nutritional interventions with traditional rehabilitation measures could provide opportunities to optimize stroke recovery outcomes. This is a patent-pending methodology that can be considered among such efforts that should be scientifically explored to provide useful insights, irrespective of whether the particular formulations will prove to be clinically effective or not. The questions asked, and directions that have been suggested, can trigger wider research on nutritional optimization as a neurological recovery, furthering the knowledge of the impact of dietary elements on the health of the brain, neuroplasticity, and post-cerebrovascular injury healing.

References

1. Allen CL and Bayraktutan U. "Oxidative stress and its role in the pathogenesis of ischaemic stroke". International Journal of Stroke 4.6 (2009): 461-470.
2. Dirnagl U, Iadecola C and Moskowitz MA. "Pathobiology of ischaemic stroke: An integrated view". Trends in Neurosciences 22.9 (1999): 391-397.
3. Donnan GA., et al. "Stroke". The Lancet 371.9624 (2008): 1612-1623.
4. Fernstrom JD and Fernstrom MH. "Tyrosine, phenylalanine, and catecholamine synthesis and function in the brain". The Journal of Nutrition 137.6 (2007): 1539S-1547S.
5. Garcion E., et al. "New clues about vitamin D functions in the nervous system". Trends in Endocrinology & Metabolism 13.3 (2002): 100-105.
6. Iadecola C and Anrather J. "The immunology of stroke: From mechanisms to translation". Nature Medicine 17.7 (2011): 796-808.
7. Katzenschlager R., et al. "Mucuna pruriens in Parkinson's disease: A double blind clinical and pharmacological study". Journal of Neurology, Neurosurgery & Psychiatry 75.12 (2004): 1672-1677.
8. Lamprecht M., et al. "Effects of zeolite supplementation on parameters of intestinal barrier integrity, inflammation, redox biology, and performance in aerobically trained subjects". Journal of the International Society of Sports Nutrition 12.1 (2015): 40.
9. Liu Z., et al. "Curcumin protects against ischemic stroke by titrating microglia/macrophage polarization". Frontiers in Aging Neuroscience 9 (2017): 233.
10. Mastinu A., et al. "Zeolite clinoptilolite: Therapeutic virtues of an ancient mineral". Molecules 24.8 (2019): 1517.
11. May JM. "Vitamin C transport and its role in the central nervous system". In: Watson RR (Ed.), Subcellular Biochemistry, Vol. 56 (2012): 85-103.
12. Murphy TH and Corbett D. "Plasticity during stroke recovery: From synapse to behaviour". Nature Reviews Neuroscience 10.12 (2009): 861-872.
13. Nobre AC, Rao A and Owen GN. "L-theanine, a natural constituent in tea, and its effect on mental state". Asia Pacific Journal of Clinical Nutrition 17.S1 (2008): 167-168.
14. Rohdewald P. "A review of the French maritime pine bark extract (Pycnogenol), a herbal medication with diverse clinical pharmacology". International Journal of Clinical Pharmacology and Therapeutics 40.4 (2002): 158-168.
15. Sinha K, Chaudhary G and Gupta YK. "Protective effect of resveratrol against oxidative stress in the middle cerebral artery occlusion model of stroke in rats". Life Sciences 71.6 (2002): 655-665.
16. Tellone E., et al. "Resveratrol: A focus on several neurodegenerative diseases". Oxidative Medicine and Cellular Longevity 2015 (2015): Article 392169.
17. Winstein CJ., et al. "Guidelines for adult stroke rehabilitation and recovery: A guideline for healthcare professionals from the American Heart Association/American Stroke Association". Stroke 47.6 (2016): e98-e169.
18. Wu J., et al. "Neuroprotection by curcumin in ischemic brain injury involves the Akt/Nrf2 pathway". PLoS ONE 8.3 (2013): Article e59843.
19. Zhao J., et al. "Curcumin improves outcomes and attenuates focal cerebral ischemic injury via antiapoptotic mechanisms in rats".

Neurochemical Research 35.3 (2010): 374-379.